CCMB develops India's first mRNA vaccine technology
India’s first indigenous mRNA (Messenger RNA) vaccine technology to combat in opposition to Covid-19 has been advanced via way of means of the Centre for Cellular and Molecular Biology (CCMB) and the Council Of Scientific And Industrial Research (CSIR). Among the main vaccine technology to be had these days to combat Covid-19, mRNA vaccines are most of the best. The global witnessed the strength of the primary mRNA vaccines in the course of the Covid-19 pandemic. Vaccines work by training our immune system to become aware of disease-inflicting microorganisms and cast off them speedy after they come across them subsequently. This is completed with mRNA vaccine technology by introducing an mRNA of the micro-organism of concern. This mRNA in the host cells offers rise to the microbial protein or part of it, which trains the immune device to evade it whilst the actual contamination occurs with the same live microorganism.
CSIR-Centre for Cellular and Molecular Biology (CCMB) is leading the development of mRNA vaccine technology in India. It has now introduced the improvement of a capacity mRNA vaccine candidate against SARS-CoV-2. India's first mRNA vaccine technology which is devoid of any technology contributions from elsewhere. The team at the Atal Incubation Centre-CCMB (AIC-CCMB) led the development of the vaccine candidate. “We observed robust immune responses against SARS-CoV-2 Spike protein in mice, upon administration of doses of the mRNA. The anti-Spike antibodies generated were found to be more than 90% efficient in preventing the human ACE2 receptor binding to the coronavirus,” stated Dr. Rajesh Iyer, a scientist worried about the project. Currently, the mRNA vaccine candidate is present process preclinical challenge research to assess its efficacy to guard against live virus infection.
“The current war with COVID-19 pandemic has brought to light many vaccine technologies, and India’s vaccine program is highly lauded. However, we lack the potent mRNA vaccine technology, as developed by Moderna or Pfizer/BioNTech to combat COVID-19 in the U.S.A and Europe. The developed technology is different from the mRNA vaccine being developed by Genova Bio, which is based on self-replicating RNA,” stated Dr. Madhusudhana Rao, CEO, AIC-CCM.
Image by Spencer Davis from Pixabay
